Tyrosine Kinase Inhibitors

Kinase Inhibitor

Cytochrome P450 3A Inducers

Carcinoma, Non-Small-Cell Lung

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Brigatinib is a kinase inhibitor. The chemical name for brigatinib is 5-chloro-N<span class="Sup">4</span>-[2-(dimethylphosphoryl)phenyl]-N<span class="Sup">2</span>-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine. The molecular formula is C<span class="Sub">29</span>H<span class="Sub">39</span>ClN<span class="Sub">7</span>O<span class="Sub">2</span>P which corresponds to a formula weight of 584.10 g/mol. Brigatinib has no chiral centers. The chemical structure is shown below:</p><div class="Figure"><img alt="Chemical Structure" src="alunbrig-01.jpg"/></div><p>Brigatinib is an off-white to beige/tan solid. The pK<span class="Sub">a</span>s were determined to be: 1.73 ± 0.02 (base), 3.65 ± 0.01 (base), 4.72 ± 0.01 (base), and 8.04 ± 0.01 (base).</p><p>ALUNBRIG is supplied for oral use as film-coated tablets containing 180 mg, 90 mg or 30 mg of brigatinib and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (Type A), magnesium stearate, and hydrophobic colloidal silica. The tablet coating consists of talc, polyethylene glycol, polyvinyl alcohol, and titanium dioxide.</p></section>

Alunbrig

brigatinib

brigatinib 30 MG Oral Tablet

brigatinib 30 MG Oral Tablet [Alunbrig]

brigatinib 90 MG Oral Tablet

brigatinib 90 MG Oral Tablet [Alunbrig]

brigatinib 180 MG Oral Tablet

brigatinib 180 MG Oral Tablet [Alunbrig]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Alunbrig is a cancer medication that stops the growth and spread of cancer cells. It is prescribed for treating metastatic non-small cell lung cancer in patients whose cancer has an abnormal "ALK" gene. Prior to prescribing Alunbrig, patients are tested for the presence of this gene.

Alunbrig is FDA approved for the following indications: ALK+ metastatic non-small cell lung cancer. 

Report Adverse Event 

Prescribing Information

Medication Guide

Submit MSL Request 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity 

Takeda Oncology Here2Assist Enrollment Form 

Takeda Oncology Here2Assist Enrollment Form - Spanish

Enroll in Patient Savings Program 

Takeda Oncology Patient Assistance Program

Takeda Oncology Patient Assistance Program - Spanish

Alunbrig Smart Trial Enrollment Form - Free 1 Month Supply

Other HCP Resources

About Alunbrig 

Taking Alunbrig

Side Effects

Patient Brochure - Newly Diagnosed

Patient Brochure - After Crizotininb Treatment

Patient Dosing Guide Brochure

Care Partner Brochure

Patient Planner

Patient Stories

Patient Information Kit

Patient Resources

Takeda Oncology Here2Assist Support Program 

Instructions For Use: NSCLC